Archives: News

News

ABC Joins National Effort Advocating for Obesity Care Coverage

As part of Obesity Care Week 2025, the Association of Black Cardiologists (ABC) proudly joined over 65 healthcare organizations in signing an open letter urging leading employers to provide comprehensive…

Join ABC in Raising Awareness for Heart Valve Disease (HVD) Awareness Day (Feb. 22)

ABC is a proud partner of National Heart Valve Disease (HVD) Awareness Day. The Association of Black Cardiologists (ABC) is proud to partner with the Alliance for Aging Research for…

Empowering Communities Through Digital Health: The Techquity by FAITH! Digital Health Advocate Training

Transforming Lives with Digital Health Advocacy The Mayo Clinic’s FAITH! (Fostering African-American Improvement in Total Health) Program, with training support from the Association of Black Cardiologists (ABC), recently completed the…

Amgen Announces Robust Weight Loss With Maritide In People Living With Obesity Or Overweight At 52 Weeks In A Phase 2 Study

MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight MariTide is the First Obesity Treatment With…

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

– Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport…

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

– Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone…